Please login to the form below

Not currently logged in


This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk to acquire metabolic disorders specialist Inversago Pharma for $1bn

Novo Nordisk to acquire metabolic disorders specialist Inversago Pharma for $1bn

Semaglutide is already available in major markets for weight management under the brand names Wegovy and Rybelsus as a once-weekly injection.

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • On our best behaviour On our best behaviour

    Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Six ways to provide successful e-learning programs to healthcare professionals
Practical tips to setting up high-impact e-learning programs...
5 ways to engage HCPs in medical education
How to bring credibility, trust and flexibility into your medical education programs...
Navigating challenges of MedTech research with rare-disease patients
Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine....